Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (43)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Kennedy, P. G.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kennedy, P. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Brain, Vol 120, Issue 7 1245-1259, Copyright © 1997 by Oxford University Press

REVIEWS

Potential use of herpes simplex virus (HSV) vectors for gene therapy of neurological disorders

PG Kennedy
Department of Neurology, Glasgow University, Southern General Hospital NHS Trust, UK.

Advances in molecular biology and virus genetics have allowed the possibility of gene therapy using viral vectors for a variety of neurological diseases in which the genetic or biochemical basis is understood. A number of such vectors have now been constructed, including those derived from herpes simplex virus (HSV), adenovirus, retrovirus and adeno-associated virus, and used in preliminary in vitro experiments and in animal models. It is possible to package a foreign gene into such a vector which can then be targeted to specific regions of the nervous system. HSV is particularly appropriate for delivering genes to neurons in view of its ability to establish latent infection in these cells. Viral vectors have the potential to be used to treat such neurological conditions as malignant gliomas, Parkinson's disease, known single gene disorders and cerebral ischaemia. However, the technical problems which will need to be overcome are formidable and will not be easily solved. The problems include the efficient delivery of the vector to target cells, the maintenance and control of foreign gene expression, and the control of unwanted host immune responses.
Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Neurol. Neurosurg. PsychiatryHome page
P G E Kennedy
Neurovirological methods and their applications
J. Neurol. Neurosurg. Psychiatry, August 1, 2003; 74(8): 1016 - 1022.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
R. M. Sapolsky
Gene Therapy for Psychiatric Disorders
Am J Psychiatry, February 1, 2003; 160(2): 208 - 220.
[Abstract] [Full Text] [PDF]

Home page
 NeuroscientistHome page
D. S. Latchman
Book Review: Gene Therapy with Herpes Simplex Virus Vectors: Progress and Prospects for Clinical Neuroscience
Neuroscientist, December 1, 2001; 7(6): 528 - 537.
[Abstract] [PDF]

Home page
 Exp. Biol. Med.Home page
T. A. Steele
Recent Developments in the Virus Therapy of Cancer
Experimental Biology and Medicine, February 1, 2000; 223(2): 118 - 127.
[Abstract] [Full Text]

Home page
 NeurologyHome page
R. M. Sapolsky and G. K. Steinberg
Gene therapy using viral vectors for acute neurologic insults
Neurology, December 1, 1999; 53(9): 1922 - 1922.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.